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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYPreservation of cell identity is necessary for homeostasis of most adult tissues. This process is challenged every time a tissue undergoes
regeneration after stress or injury. In the lethal Duchenne muscular dystrophy (DMD), skeletal muscle regenerative capacity declines
gradually as fibrosis increases. Using genetically engineered tracing mice, we demonstrate that, in dystrophic muscle, specialized cells
of muscular, endothelial, and hematopoietic origins gain plasticity toward a fibrogenic fate via a TGFb-mediated pathway. This results
in loss of cellular identity and normal function, with deleterious consequences for regeneration. Furthermore, this fibrogenic process in-
volves acquisition of a mesenchymal progenitor multipotent status, illustrating a link between fibrogenesis and gain of progenitor cell
functions. As this plasticity also was observed in DMD patients, we propose that mesenchymal transitions impair regeneration and
worsen diseases with a fibrotic component.INTRODUCTION
Successful regeneration after tissue injury requires timely
coordinated actions of diverse cell types. In skeletalmuscle,
in response to acute damage, the muscle stem cell (satellite
cell) progeny gives rise to new regenerating myofibers,
aided by the concerted action of specialized cells, such
as infiltrating bone-marrow-derived inflammatory cells,
which phagocytose tissue debris and provide pro-
myogenic growth factors and cytokines; fibrogenic stromal
cells such as fibroblasts and adipogenic progenitors (FAPs),
which provide transient matrix support; and angiogenic
cells that vascularize the newly formed muscle tissue
(Abou-Khalil et al., 2010; Mounier et al., 2011). In chroni-
cally damaged muscle, however, this coordination is lost,
leading to deficient regeneration (Serrano et al., 2011). In
the yet incurable Duchenne muscular dystrophy (DMD),
caused by loss of the myofiber protein dystrophin, succes-
sive cycles of tissue degeneration and regeneration lead to
an eventual muscle regenerative failure and replacement
of dystrophic muscle by fibrotic tissue, resulting in respira-
tory failure and early death (Mann et al., 2011; Stedman
et al., 1991; Wallace and McNally, 2009).
Cell plasticity (i.e., the capacity of cells to change their
phenotypic properties) is inherent to organismal develop-
ment and is becoming increasingly associated with tissue
remodeling in the adult (Medici and Kalluri, 2012; Nieto,
2013). Mesenchymal transitions (particularly epithelial-
and endothelial-to-mesenchymal transitions, EMTs and1046 Stem Cell Reports j Vol. 4 j 1046–1060 j June 9, 2015 j ª2015 The AutEndMTs, respectively) are connected both to fibrotic pa-
thologies and cancer progression of distinct etiologies,
affecting organs such as liver, lung, heart, or kidney (Medici
and Kalluri, 2012; Nieto, 2013; Nieto and Cano, 2012; Zeis-
berg and Kalluri, 2013). Lineage-tracing and fate-mapping
strategies have precisely determined and quantified the
source of fibrogenic cells in fibrotic kidney, underscoring
the relevance of EMT, EndMT, and bone-marrow-derived
cells to this organ’s fibrosis (LeBleu et al., 2013). Incomplete
EMT also can occur in tumors, with cells acquiring mesen-
chymal properties without undergoing the full EMT as it
also occurs in embryos, where intermediate phenotypes
have been described in different contexts (Nieto, 2011,
2013; Nieto andCano, 2012). These incomplete transitions
implicate a change in cellular functions and behavior. In
skeletal muscle, studies on cell plasticity during repair are
emerging. In addition to resident interstitial fibroblasts
and FAPs, which are considered the major producers of
the collagen-rich extracellular matrix (ECM) in injured
muscle and in young dystrophic muscle (Joe et al., 2010;
Mann et al., 2011; Uezumi et al., 2011, 2014), perivascular
progenitor cells transiently produce collagen in response
to acute muscle damage, but disappear as regeneration ad-
vances (Dulauroy et al., 2012). Similarly, depletion of mac-
rophages or age-induced Wnt signaling in acutely injured
muscle can divert vascular and myogenic cell fates, respec-
tively (Brack et al., 2007; Zordan et al., 2014). However,
whether cell plasticity occurs in dystrophic muscle and
how it affects disease progression have remained elusive.hors
Recently, fibrogenesis from muscle cells has been reported
in DMD (Biressi et al., 2014).
Here we demonstrate that specialized cells of muscular,
endothelial, and hematopoietic origins acquire mesen-
chymal-fibrogenic traits in dystrophic muscle, with this
cellular plasticity being particularly associated with
advanced DMD stages. The mesenchymal-fibrogenic plas-
ticity of these cells is induced by increasing TGFb signaling
in dystrophic muscle with aging, and results in the loss of
cell identity, thus precluding normal regenerative func-
tions. Together, our findings suggest that, during efficient
tissue repair, specialized cells preserve their lineage identity
by avoiding entrance into a mesenchymal-like/fibrogenic
state. This protection is lost in chronic degenerative condi-
tions such as DMD.RESULTS
The levels of TGFb and downstream signaling mediators
(activated SMAD2/3) increase in muscle of dystrophic
mdx mice with age, correlating to reduced regeneration,
angiogenesis and function, and higher fibrosis extent
(Ardite et al., 2012; Kharraz et al., 2014; Mann et al.,
2011; Vidal et al., 2008; Figure 1A; Figures S1A and S1B).
Inflammatory cells and FAPs appeared as the principal
sources of TGFb in dystrophic muscle (Figure S1C). Higher
levels of this pathway also were found in muscle of wild-
type (WT) mice after laceration (a severe injury model
that induces persistent degeneration and more sustained
fibrosis) than after cardiotoxin (CTX) injury (in which
collagen-rich ECM is transient and full regeneration and
muscle function are achieved rapidly) (Figures S1D and
S1E). In agreement with the profibrotic role of TGFb, exog-
enous delivery of TGFb to CTX-injured WT muscle or
dystrophic muscle of young mdx mice delayed regenera-
tion and vascularization, while promoting fibrogenesis.
This suggests that TGFb inhibits myogenic and angiogenic
capacity of muscle stem cell (satellite cell)-derived myo-
blasts and endothelial cells, respectively, while promoting
matrix accumulation (Figures S1F and S1G). Consistent
with this, freshly isolated WT satellite cells were unable to
fuse into myotubes in differentiation medium (DM) in
the presence of TGFb (Figure S2A), correlating with gain
of expression of fibrogenic genes (aSma, Collagen I, Eda-
Fibronectin, orTimp1) and loss ofmyogenic gene expression
(Myf5 and Pax7) after a 10-day treatment (Figure S2B). Like-
wise, endothelial cells isolated from skeletal muscle could
not form angiotubes in vitro after a 10-day TGFb treatment
period (Figure S2C), consistent with loss of expression of
endothelial genes (Cd31 and Tie1) and de novo acquisition
of fibrogenic traits (Figure S2D). These results indicate that
TGFb induces the loss of identity of muscle-residentStem Cmyogenic and endothelial cells by promoting their switch
into matrix-producing fibrogenic cells, thus precluding
their bona fide functions.
To further understand this cellular plasticity process
induced by TGFb, we performed a microarray gene expres-
sion analysis of satellite cells treated (or not) with TGFb
for 4 days (before achieving maximal levels of fibrogenic
conversion, i.e., expression of aSma [Figure S2B]). Gene
ontology functional annotation of genes upregulated in
TGFb-treated myogenic cells, compared to non-treated
cells, showed enrichment in mesenchymal-fibrogenic
functions (Figure S3A). Moreover, after comparison with
a curated list of mesenchymal progenitor cell-specific
transcripts (Kubo et al., 2009), we identified a group of
mesenchymal cell-specific genes induced by TGFb (Fig-
ure S3A). qRT-PCR analysis of a TGFb cell-treatment
kinetics experiment validated the expression of mesen-
chymal progenitor genes at intermediate time points (Fig-
ure 1B). These mesenchymal genes were also significantly
upregulated in endothelial cells isolated from skeletal
muscle in response to identical TGFb treatment, prior to
larger acquisition of fibrogenic traits (Figure 1B; see
scheme in Figure 1C).
To prove whether this gain of mesenchymal gene expres-
sion translated into de novo functional cellular multipo-
tency (i.e., potential to differentiate into distinct cellular
fates), satellite cells and endothelial cells were treated with
TGFb for 3 days and further incubated with osteogenic or
adipogenic medium for 7–14 days, or they continued to
be treated with TGFb for 7 extra days. Notably, cells pre-
treatedwithTGFb showed induced expressionof adipocyte,
osteoblast, or fibrogenic traits under their respective differ-
entiation regimes (Figures 1D and 1E; Figure S3B); in
contrast, cells that had not been pretreated with TGFb did
notundergoanyof these conversionsunder identical differ-
entiation conditions (Figures 1D and 1E). These results sug-
gest that these two specialized cell types (myogenic and
endothelial cells) gain expression of mesenchymal genes
during the plastic process toward a more mature fibrogenic
fate in response to TGFb; furthermore, these cells exhibit
multipotency under adequate culture conditions (see
scheme in Figure 1C). Of note, TGFb was capable of
inducing the expression of transcription factors and
microRNAs associated with mesenchymal transitions in
myogenic and endothelial cells (Figures S3C and S3D). In
particular, Mir21 induction appeared to mediate TGFb-in-
duced fibrogenesis in both cell types (Figure 2), reinforcing
thisMir as a fibrogenic effector of TGFb action (Acun˜a et al.,
2014; Ardite et al., 2012; Kumarswamy et al., 2012).
Since TGFb levels and signaling are elevated in aged
dystrophic muscle (Figure 1A), we next investigated
whether endothelial and satellite cells also undergo plastic
fibrogenesis in vivo. To this end, we generated endothelialell Reports j Vol. 4 j 1046–1060 j June 9, 2015 j ª2015 The Authors 1047
Figure 1. Increased TGFb Signaling at Advanced Muscular Dystrophy Stages and TGFb-Induced Cellular Plasticity
(A) Active TGFb protein levels (ELISA) in limb muscles of mdx mice (C57BL/6 background) at distinct ages: young (2–3 months), adult
(6–10 months), and old (18–24 months). Data correspond to the mean ± SEM values; n = 10 for each group. Non-parametric Mann-Whitney
U test was used for comparison. Representative pictures of phosphorylated SMAD2/3 (P-SMAD2/3) protein immunostaining in mdx muscles
are shown. *P-Smad2/3-positive cells. Scale bar, 50 mm.
(legend continued on next page)
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Figure 2. Mir-21 Mediates TGFb-Induced
Fibrogenesis of Satellite Cells and Endo-
thelial Cells
(A and B) Satellite cells (A) and endothelial
cells (B), transfected with Ant-Mir-21 or
Scramble oligomiR, were treated with TGFb
for 8 days, and subjected to qRT-PCR for fi-
brogenic, myogenic or endothelial markers,
respectively. Values are mean ± SEM; n = 3
independent experiments. Unpaired t test
was used for comparison.and satellite cell-lineage-tracing mice in two mdx dystro-
phic backgrounds, DBA/2 and C57BL/6, which develop
substantial fibrosis in limb muscles at adult (6–10 months)
or old (after 18 months) age, respectively (Fukada et al.,
2010; Figures S4A and S4B). First, Ve-Cad-CreER/YFP mice
(obtained by intercrossing of Cdh5(Ve-Cad)-CreER and
Rosa26R-YFP mice, in which the expression of Cre is
induced exclusively in adult endothelial cells expressing
Ve-Cadherin upon tamoxifen administration) were inter-
crossed with mdx/DBA/2 mice, generating Ve-Cad-CreER/
YFP/mdx triple-mutant mice, which were aged until(B) Heat map representing qRT-PCR of fibroblastic, myogenic, and mes
cells treated with TGFb for the indicated time points (days). Values a
(C) Summary scheme representing the process of fibrogenic plasticity o
injured skeletal muscle. Scheme is inferred from results using satellit
without treatment with TGFb. Kinetics of fibrogenic cell plasticity indu
progenitor cell-like state, which in turn is endowed with multipotent
mice for endothelial and satellite cells in mdx dystrophic background
tracing) and in WT muscle after CTX injury/TGFb administration. Endot
identities and functions in vivo (become CD31low/ or a7-integrinl
shown]). During this process, these cells express the mesenchymal pr
lineage-differentiation conditions (see D and E). We also detecte
(i.e, fibrocytes characterized by co-expression of CD45 and COLLAGEN
(D and E) Multipotency analysis of TGFb pre-treated endothelial cells (
and fibrogenic DM. Oil Red O (adipogenic), alkaline phosphatase (oste
multi-lineage potential compared to non-pre-treated cells. Scale bars
Stem Cadvanced fibrogenic stages (i.e., 6–10 months). A second
endothelial genetic tracing line, Tie2-Cre/YFP mice (ob-
tained by intercrossing of Tie2-Cre and Rosa26R-YFP
mice, in which the Tie2 gene is expressed by endothelial
cells from early vascular development), was bred into the
mdx/C57BL/6 dystrophic background, generating Tie2-
Cre/YFP/mdx triple-mutant mice, which were subse-
quently aged up to 18–24months for fibrosis development.
Use of the CD31 endothelial cell marker in a YFP+-
based sorting protocol permitted discrimination between
bona fide endothelial cells (YFP+CD31high) and cells ofenchymal stem cell marker expression in satellite cells or endothelial
re mean ± SEM; n = 3 independent experiments.
f myogenic, endothelial, and hematopoietic cells in dystrophic and
e cells and endothelial cells obtained from skeletal muscle, with or
ced by TGFb is represented, with cells transiting via a mesenchymal
capacity. Similar plastic changes occur in muscle of lineage-tracing
(or in bone-marrow-transplanted mdx mice for hematopoietic cell
helial and satellite cells gain fibrogenic plasticity and lose their own
ow/, and have reduced angiogenic and myogenic potential [not
ogenitor marker PDGFRa and exhibit multipotency under adequate
d fibrogenic cells of hematopoietic origin in dystrophic muscle
I).
D) and satellite cells (E), further cultured in adipogenic, osteogenic,
ogenic), and COLLAGEN or FIBRONECTIN (fibrogenic) staining detect
, 50 mm.
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endothelial origin that had reduced (or lost) expression of
CD31 (YFP+CD31low/). The YFP+CD31high cells repre-
sented the most prominent YFP+ cell population in Ve-
Cad-CreER/YFP and Tie2-Cre/YFP (WT) muscle (Figures 3A
and 3B). In fibrotic-dystrophic muscle, however, a YFP+
CD31low/ cell population was induced (Figures 3A and
3B). Fibrogenic markers (Collagen I and Fibronectin) were
found exclusively in the YFP+CD31low/ cell fraction (Fig-
ure 3C), which accounted for approximately 20%–25% of
the endothelial cell population (Figures 3A and 3B), and
this was confirmed by qRT-PCR (Figure 3D), supporting
the occurrence of cell plasticity characterized by the reduc-
tion of endothelial identity traits and acquisition of the fi-
brogenic gene program, at advanced muscular dystrophy.
This conclusion was confirmed by the detection of cells
double positive for fibrogenic and endothelial cell markers
in muscle at late dystrophic stages (Figure S4C; Figure 3E),
which coincided with the reduced vascularization and
regeneration and increased fibrosis (Figure S1B). Further-
more, delivery of TGFb to CTX-injured muscle of Ve-Cad-
CreER/YFP mice induced the presence of YFP+CD31low/
fibrogenic cells (Figure 3F), although to a lesser extent
than in dystrophic muscle (Figures 3A and 3B). qRT-PCR
and immunofluorescence analysis confirmed the reduction
of endothelial cell markers and gain of fibrogenic ones in
the YFP+/CD31low/-sorted cells in TGFb/CTX-injured WT
muscles (Figures S4D and S4E).
Next, using a similar lineage-tracing strategy, we gener-
ated Pax7-Cre/YFP double-transgenicmice (obtained by in-
tercrossing Pax7-Cre and Rosa26R-YFP mice, in which the
expression of Cre is induced in Pax7-expressingmuscle pre-
cursor cells) that were intercrossed with mdx/C57BL/6
dystrophic mice, and the resulting Pax7-Cre/YFP/mdx tri-
ple-mutant mice were aged up to 18–24 months. We also
used Pax7-CreER/YFP mice (in which Cre is induced only
in adult satellite cells upon tamoxifen administration)
that were intercrossed with mdx/DBA/2 mice, generating
Pax7-CreER/YFP/mdx triple-mutant mice, which wereFigure 3. Fibrogenic Plasticity of Endothelial Cells at Advanced M
(A) Representative FACS plots of CD31 expression in YFP+ cells from d
CreER/YFP (WT) muscle. Mdx mice were in the DBA2 background and a
(B) Quantification of YFP+ cells with reduced/lost CD31 expression in V
Tie2-Cad-Cre/YFP/mdx mice in C57BL/6 background at old age. Valu
Mann-Whitney U test was used for comparisons.
(C) Immunofluorescence analysis of FACS-isolated cells from (B): YFP
losing CD31 expression (CD31low/). Nuclei are stained with DAPI. Sc
(D) qRT-PCR in FACS-isolated YFP+CD31low/ cells from Ve-Cad-CreER
fibroblastic and endothelial cell markers. Values are mean ± SEM; n = 6
used for comparison.
(E) Representative immunostaining shows YFP+ cells co-expressing fib
(F) Representative FACS plots of CD31 expression in YFP+ cells isolated
initial injury [Figure S1F]) of Ve-Cad-CreER/YFP mice, and quantificatio
SEM; n = 6 animals for each group. Non-parametric Mann-Whitney U
Stem Caged until advanced fibrogenic stages at adult age
(6–10 months). Double-labeling cell sorting for YFP and
the satellite cell marker a7-INTEGRIN allowed us to
discriminate between bona fide satellite cells (YFP+a7high)
and cells that had reduced or lost (YFP+a7low/) a7-
INTEGRIN expression after CTX/TGFb injury and in aged
dystrophic mice. The YFP+a7low/ cell population was
induced specifically in CTX/TGFb-injured muscle (com-
pared to CTX-injured, or non-injured, muscle) of Pax7-
CreER/YFP mice (Figure 4A). This population was further
increased (up to 11%–15%) in Pax7-CreER/YFP/mdxmuscle
of adult age (BDA/2 background) or old age (C57BL/6 back-
ground) (Figure 4B; Figure S4F). Supporting the decline in
myoblast cell identity in vivo, the expression of Pax7
decreased, while fibroblastic gene transcripts increased in
YFP+a7low/ cells frommdx and TGFb/injured WTmuscles
(Figures 4C and 4D). Furthermore, in myofiber explants,
the number of bona fide satellite cells associated with
each myofiber decreased in fibrotic Pax7-Cre/YFP/mdx
mice, as indicated by the lower number of YFP+ cells ex-
pressing PAX7 orMYOGENIN (markers of quiescent/prolif-
erating or differentiated myogenic cells, respectively),
compared to age-matched WT myofibers (Figure 4E).
Conversely, YFP+ cells in mdx myofiber explants gained
expression of fibrogenicmarkers (Figure 4E). Co-expression
of fibrogenic and myogenic proteins (or YFP) (Figure S4G;
Figure 4F) further supported satellite cell fibrogenic plas-
ticity in aged dystrophic muscle. Together, based on quan-
tifications of these analyses (Figures 4B and 4E; Figure S4F),
11.7%of cells ofmyogenic origin gained fibrogenic traits in
aged dystrophic muscle.
We subsequently tested the functional consequences of
this fibrogenic plasticity in dystrophic muscle. The fluores-
cence-activated cell sorting (FACS)-isolated cells of endo-
thelial and myogenic origins (YFP+) that had reduced
(or lost) expression of CD31 or a7-INTEGRIN (YFP+
CD31low/ or YFP+a7low/) showed a severely impaired ca-
pacity to form angiotubes andmyotubes in pro-angiogenicuscular Dystrophy Stages and in Response to TGFb
ystrophic Ve-Cad-CreER/YFP/mdx (mdx) muscle compared to Ve-Cad-
nalyses were performed at adult age.
e-Cad-CreER/YFP/mdx mice in DBA2 background at adult age and in
es are mean ± SEM; n = 6 animals for each group. Non-parametric
+ cells that gain PRO-COLLAGEN and FIBRONECTIN expression while
ale bars, 50 mm.
/YFP/mdx mice compared to YFP+CD31high cells for the indicated
independent experiments (mice) for each group. Unpaired t test was
rogenic markers in Ve-Cad-CreER/YFP/mdx mice. Scale bars, 25 mm.
from CTX-injured and CTX/TGFb-injured muscle (after 14 days of the
n of YFP+ cells with reduced/lost CD31 expression. Values are mean ±
test was used for comparison.
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Figure 4. Fibrogenic Plasticity of Satellite Cells at Advanced Muscular Dystrophy Stages and in Response to TGFb
(A) Representative FACS plots of a7-INTEGRIN expression in CTX-injured and CTX/TGFb-injured Pax7-CreER/YFP muscles (as in Figure S1F)
and quantification of YFP+ cells that have reduced/lost a7-integrin expression. Values are mean ± SEM; n = 6 animals for each group. Non-
parametric Mann-Whitney U test was used for comparison.
(legend continued on next page)
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and pro-myogenic differentiation conditions, respectively
(Figure 4G). Despite the significant fraction of both endo-
thelial and myogenic cells undergoing fibrogenic plasticity
in dystrophic muscle, surprisingly, each cell type only
constituted about 2% of the bona fide active collagen-ex-
pressing cell population (i.e., active fibroblasts), based
on intracellular collagen protein staining of the YFP+
CD31low/ and YFP+a7low/ cell populations, respectively
(Figure S5A). Similarly, using a ColI-GFP reporter mice (in
which GFP expression is under the control of the Collagen
I promoter), only a low percentage of CD31+ and a7-
INTEGRIN+ cells were found within the fibroblastic
(GFP+) cell population (Figure S5B). These findings strongly
suggest that, unlike other fibrotic organs, such as kidney
(LeBleu et al., 2013), these fibrogenic changes do not lead
to full and ample transformation into collagen-producing
cells. Instead, this fibrogenic plasticity mainly precludes
efficient myogenesis and angiogenesis and it impairs tissue
repair.
We next investigated if endothelial and satellite cells also
transit through intermediate mesenchymal progenitor
states during the process of fibrogenesis in diseasedmuscle.
To this end, we set up a FACS protocol based on the use
of the cell surface mesenchymal progenitor marker
PDGFRa (Chong et al., 2013; Pinho et al., 2013; Uezumi
et al., 2010, 2014). A subpopulation of YFP+ cells that
were low for CD31 or a7-INTEGRIN expression appeared
positive for PDGFRa (YFP+PDGFRa+) in fibrotic muscles
of dystrophic lineage-tracing mice (Figures 5A and 5B).
The YFP+PDGFRa+CD31low/ and YFP+PDGFRa+a7low/
populations represented 14.6% and 16.3% of the fibro-
genic YFP+CD31low/ and YFP+a7low/ cell fractions in
adult mdx muscle, respectively (Figures 5A and 5B), and
these percentages even increased inoldermice (Figure S5C).
As for the YFP+CD31low/ and YFP+ a7low/ cell fractions,
the PDGFRa+-expressing cell subpopulations were inca-
pable of forming myotubes or angiotubes under appro-
priate differentiation conditions (not shown). The
qRT-PCR analysis confirmed induction of mesenchymal
progenitor markers in the freshly isolated YFP+PDGFRa+(B) Quantification of YFP+ cells that maintain or have reduced/lost a7
to Pax7-CreER/YFP (WT) mice. Values are mean ± SEM; n = 6 animals
comparison.
(C and D) qRT-PCR of fibroblastic and myogenic markers in YFP+a7low/
and from CTX/TGFb-injured Pax7-CreER/YFP muscle (D). Values are m
Unpaired t test was used for comparison.
(E) Percentage of YFP+ cells that express myogenic and fibrogenic mark
Pax7-Cre/YFP (WT) mice. Values are mean ± SEM; n = 5 animals each gr
(F) Representative immunostaining shows YFP+ cells co-expressing fi
(G) Myogenic potential of FACS-isolated YFP+a7high cells from aged Pax
DM for 4 days. The angiogenic potential of CD31high versus CD31low/
conditions (see Experimental Procedures). Scale bars, 50 mm.
Stem CCD31low/ and YFP+PDGFRa+a7low/ subpopulations
from dystrophic muscle (Figure 5C). Thus, during the pro-
cess of endothelial and satellite cell plasticity toward fibro-
genesis, a fraction of cells shows mesenchymal progenitor
traits. This was consistent with a subpopulation of YFP+
endothelial or myogenic cells also gaining PDGFRa+
expression in WT muscle subjected to CTX/TGFb injury
(Figure 5D). Consistent with the notion that TGFb
signaling is a driving cause for these plastic mesenchymal
transitions, we could detect co-expression of activated
SMAD2/3 in PDGFRa+/YFP+ cells in muscle of the distinct
lineage-tracing mice (in various muscle degeneration/
fibrosis paradigms) (Figure 5E; Figure S5D; data not shown)
and in human DMD (see below).
To finally prove that these subpopulations of YFP+
PDGFRa+ cells (from endothelial or myogenic origin) are
indeed mesenchymal in nature, we tested their multipo-
tency (the capacity to be coaxed to differentiate into
distinct terminal fates: fat, bone, cartilage, or scar/fibrous)
if exposed to adequate conditions. YFP+PDGFRa+ cells
were FACS isolated from muscle of lineage-tracing dystro-
phic mice and subsequently cultured with osteogenic, adi-
pogenic, or chondrogenic differentiation media or with
TGFb (for fibrogenic differentiation). In response to these
treatments, sorted cells that had gained PDGFRa+ expres-
sion (YFP+PDGFRa+ cells), but not YFP+PDGFRa cells,
were positive for oil red staining (adipocyte), alkaline phos-
phatase staining (osteoblast), or collagen staining (fibro-
blast) (Figures 5F and 5G). In contrast, YFP+ cells, which
were PDGFRaCD31low/ or PDGFRaa7low/, did not
show multipotency (not shown), indicative of a more
differentiated fibrogenic state. These results suggest that
the process of fibrogenic plasticity of endothelial and
myogenic cells within dystrophic muscle, as with the
plastic response to TGFb in vitro (see Figure 1), involves
multipotent progenitor cell intermediate states. Of note,
in vivo interference with PDGFRa signaling with imatinib
(a tyrosine kinase inhibitor), which has been shown to
target PDGFRa-expressing mesenchymal progenitor cells
(Ito et al., 2013; Uezumi et al., 2014), prevented the loss-INTEGRIN expression in Pax7-CreER/YFP/mdx (mdx) mice compared
for each group. Non-parametric Mann-Whitney U test was used for
compared to YFP+a7high cells from Pax7-CreER/YFP/mdx muscle (C)
ean ± SEM; n = 3 independent experiments (mice) for each group.
ers in single fibers from Pax7-Cre/YFP/mdx (mdx) mice compared to
oup. Non-parametric Mann-Whitney U test was used for comparison.
brogenic markers in Pax7-CreER/YFP/mdx mice. Scale bars, 25 mm.
7-Cre/YFP/mdxmice, compared to YFP+a7low/ cells, after culture in
endothelial cells was similarly determined in angiogenic-promoting
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of cell identity in injured muscle in response to TGFb
(Figure S5E).
Mesenchymal cells in the bone marrow are multipotent
in nature. Since fibrocytes (defined as bone-marrow-
derived cells expressing the hematopoietic marker Cd45
and Collagen I) contribute to fibrosis in organs such as kid-
ney, liver, lung, and heart (Duffield et al., 2013; Kisseleva
and Brenner, 2012; Krenning et al., 2010), we hypothe-
sized that fibrocytes also could contribute to fibroblast het-
erogeneity and fibrosis in dystrophic muscle. To test this
possibility, we transplanted bone marrow from ColI-GFP
reporter mice into young (3-month-old) mdx/C57BL/6
mice, and the transplanted mice were aged for fibrosis
development for 18 extra months. A significantly
increased number of GFP+ cells was found in the muscle
of transplanted dystrophic mice of 22 months of age (as
an indication of collagen-producing cells derived from
the donor bone marrow) compared to muscle of similarly
transplanted non-dystrophic mice (Figure 5H). Consistent
with this, compared to GFP+ cells from transplanted WT
muscles, the FACS-isolated GFP+ cell population in aged
dystrophic muscle showed reduced expression of the
Cd45 hematopoietic cell marker, while the expression of
fibrogenic markers increased (Figure 5I), and this was in
agreement with the detection of cells co-expressing fibro-
genic and hematopoietic markers in advanced muscle dis-
ease stages (Figure S5F). As for endothelial and satellite
cells, only 2%–3% of fibrocytes appeared to contribute to
the overall population of collagen-expressing cells in
dystrophic muscle (Figures S5A and S5B). Together, these
results demonstrate the acquisition of fibrogenic traits
by hematopoietic cells at advanced fibrotic states of
muscular dystrophy, and further illustrate the existence
of mesenchymal plasticity of distinct specialized cells inFigure 5. Mesenchymal Progenitor Cells of Endothelial and Myoge
(A and B) Percentage of double-positive YFP+ PDGFRa+ cells from mus
(A) and Pax7-CreER/YFP/mdx (that were a7-INTEGRINhigh or a7-iINTE
lineage-tracing mice in non-dystrophic background; n = 6 animals f
comparison.
(C) qRT-PCR of mesenchymal stem cell markers in YFP+/PDGFRa+ cells w
in (B), or CD31high or CD31low expression from mice in (A, left). Value
group.
(D) Percentage of YFP+ cells that express PDGFRa in CTX/TGFb-injure
Values are mean ± SEM; n = 4–6 for each group. Non-parametric Man
(E) Representative immunostaining shows P-SMAD2/3 in PDGFR+/YFP
(F and G) Multipotency analysis of FACS-isolated YFP+PDGFRa+a7low a
Cad-CreER/YFP/mdx muscle (G), cultured in adipogenic, osteogenic, an
to growth medium (GM)-cultured cells. Oil Red O, alkaline phosphatas
bars, 50 mm.
(H) Percentage of GFP+ cells in muscles of 22-month-old mdx mice, a
mean ± SEM; n = 3 animals for each group. Non-parametric Mann-Wh
(I) qRT-PCR for fibrogenic markers and CD45 of GFP+-sorted cells afte
independent experiments (mice) for each group. Unpaired t test was
Stem Cdystrophic muscle, with deleterious consequences on dis-
ease progression.
As in dystrophic mice, we found that fibrosis was specif-
ically induced in muscles of human DMD patients
(compared to healthy individuals), being more prominent
in affected patients between 6 and 8 years of age than in
younger 2- to 4-year-old children (Figure 6A), and this
correlatedwith disease severity and physical incapacitation
(not shown). We also detected fibrogenic (TCF4+) cells in
fibrotic muscle of DMD patients that increased with age
(Figure 6A). In DMD muscles, we also identified fibrogenic
cells co-expressing vWF (a marker of endothelial cells),
CD56 (a marker of human satellite cells), and CD45 (a he-
matopoietic marker) (Figure 6B), demonstrating cell plas-
ticity in the human pathology, as in mdx dystrophic
mice (Figures S4C, S4G, and S5F; Figures 3, 4, and 5).
Because active TGFb levels and signaling (P-SMAD2/3)
also were increased in human DMD muscles, as fibrosis
and disease severity progressed with age (Figure 6C), and
because activated SMAD2/3 was specifically associated
with cells expressing markers of fibrogenic and specialized
cells in human and murine dystrophic muscle (Figures 6C
and 6D; Figure S5D), these results, taken together, reinforce
the idea of TGFb being a plasticity-promoting factor in
DMD. Consistent with this, DMD muscles contained cells
expressing the mesenchymal progenitor cell marker
PDGFRa together with markers of endothelial, myogenic,
and hematopoietic cells, respectively (Figure 6E), and
PDGFRa-expressing cells that were double positive for
P-SMAD2/3 and TCF4 (Figure 6D). Thus, in muscle of
DMD patients, as in dystrophic mice, fibrogenic cells are
a heterogeneous population, and part of these cells may
arise from plastic events within the TGFb-enriched dystro-
phic milieu. Consistent herewith, human myoblasts alsonic Origins from Dystrophic Muscle Exhibit Multipotent Capacity
cles of Ve-Cad-CreER/YFP/mdx (that were CD31high or CD31low) mice
GRINlow) mice (B). Values are mean ± SEM relative to age-matched
or each group. Non-parametric Mann-Whitney U test was used for
ith either a7-INTEGRINhigh or a7-INTEGRINlow expression from mice
s are mean ± SEM; n = 3 independent experiments (mice) for each
d versus CTX-injured muscles from the indicated mouse genotypes.
n-Whitney U test was used for comparison.
+ cells in Ve-Cad-CreER/YFP/mdx muscle. Scale bars, 10 mm.
nd YFP+PDGFRa+CD31low from Pax7-Cre/YFP/mdx muscle (F) and Ve-
d fibrogenic differentiation-promoting conditions (DM), compared
e, and aSMA staining are shown (n = 3 biological replicates). Scale
fter transplantation of bone marrow from ColI-GFP mice. Values are
itney U test was used for comparison.
r bone marrow transplantation (H). Values are mean ± SEM; n = 3
used for comparison.
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Figure 6. Fibrogenic Plasticity in Human Muscle of DMD Patients
(A) Representative Sirius Red and TCF4 staining in human muscle biopsies from healthy individuals and DMD patients 3 and 8 years of age
are shown.
(legend continued on next page)
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showed fibrogenic plasticity in vitro in response to TGFb
treatment (Figure 6F). Moreover, in vivo inhibition of
TGFb signaling, via the administration of LY2157299
(a specific inhibitor of the TGFb receptor type 1 kinase)
(Zhou et al., 2011) in old dystrophic mdx mice, reduced
the presence of collagen-producing cells co-expressing
markers of the specialized lineages (Figure 6G), while
reducing fibrosis and restoring dystrophic muscle regener-
ation and vascularization (Figure 6G). Altogether, these re-
sults unveil TGFb as a driver of fibrogenic cell plasticity
both in human and mouse dystrophic and severely
damaged muscle.DISCUSSION
Our study provides insights into the mechanisms underly-
ing the loss of regenerative potential and increasing fibro-
genesis with age in DMD. We report that a proportion of
specialized cells, which are critical for muscle regeneration,
cannotmaintain their identifying functions in aged dystro-
phic muscle of humans and mice, and acquire instead the
capacity to produce matrix proteins. This is in agreement
with a recent report from the Rando group (Biressi et al.,
2014). Fibrogenesis in dystrophic muscle does not appear
to be an all-or-nothing but rather a partial transition, as
most cells share original as well as new fibroblastic traits,
resembling the partial EMTs occurring in carcinosarcomas
and fibrotic liver (Nieto, 2013; Sarrio´ et al., 2008; Zeisberg
et al., 2007). This cellular plasticity, however, hampers
muscle tissue repair potential. Mechanistically, we show
that the loss of cell identity toward fibrogenesis in dystro-
phic muscle may involve the acquisition of mesenchymal
traits, triggered by increasing TGFb as disease progresses.
This link between skeletal muscle fibrogenesis and mesen-
chymal-like transitional states, resulting in the loss of
regenerative potential, was a striking finding. Because adi-
pose tissue also accumulates in muscle of DMD patients,(B) Representative picture of co-staining of TCF4 with endothelial,
muscles. Nuclei are stained with DAPI.
(C) Representative picture of P-SMAD2/3 staining and active TGFb p
patients 6–8 years of age. Data correspond to the mean ± SEM; n = 1
comparison.
(D) Representative immunostaining shows human cell co-expressing
(E) Representative immunostaining shows human cells expressing P
with DAPI.
(F) Human myoblasts were treated with TGFb or vehicle for 6 days a
mean ± SEM; n = 3 independent experiments for each group. Unpaire
(G) Reduction of GFP+ cells co-expressing CD31, a7-INTEGRIN, or C
signaling inhibitor LY2157299 (or vehicle) for 1 month. Quantificati
larization. Data correspond to the mean ± SEM; n = 3 for each group. N
bars, 50 mm.
Stem Cwe postulated that the loss of identity of specialized cells
concomitantly with the acquisition of mesenchymal-like
(multipotent) characteristics might be a general feature
for fibrogenesis as for adipogenesis in DMD, and by exten-
sion in other pathological conditions coursing with high
TGFb signaling and tissue damage. Indeed, TGFb2- or
BMP4-induced EndMT into multipotent stem-like cells
was proposed to be the origin of heterotopic cartilage and
bone in individuals with fibrodysplasia ossificans progres-
siva (FOP) lesions (Medici et al., 2010). A distinct muscle-
resident multipotent progenitor additionally was proposed
as an origin for FOP, based on its osteogenic potential in
response to BMP2 (Wosczyna et al., 2012).
Recent studies have shown that, in addition to fibro-
blasts, tissue-resident FAPs and perivascular cells, which ex-
press PDGFRa, can differentiate to a fibroblastic fate and
contribute to collagen accumulation in acutely injured
muscle (Dulauroy et al., 2012; Joe et al., 2010; Uezumi
et al., 2010). FAPs also accumulate in young dystrophic
muscle prior to maximal fibrosis (Uezumi et al., 2011), be-
ing the main source of the fibrogenic progeny leading to
collagen production at early dystrophy stages. Our results
demonstrate that at advanced DMD stages there are addi-
tional reservoirs of fibrogenic cells derived frommyogenic,
endothelial, and hematopoietic cells. However, unlike
organs like kidney, where a great proportion of the fibrotic
cells arise from the bone marrow (and to a lesser extent
from EndMT or EMT) (LeBleu et al., 2013), in dystrophic
skeletal muscle, the net contribution of these cells to
the actual population of collagen-producing cells (the key
cells for fibrosis development) is modest. Instead, our
results reveal that it is the loss of myogenic and endothelial
cells’ biochemical and phenotypic identities, through
plastic mesenchymal transitions (characterized by the
expression of PDGFRa), that causes severe deficits in
myogenesis and angiogenesis, thus exacerbating the regen-
erative impairment in dystrophic muscle (see scheme in
Figure 1). Therapeutically, a unifying model of loss of cellmyogenic, and hematopoietic cell markers, respectively, in DMD
rotein levels in muscle biopsies from healthy individuals and DMD
0 in each group. Non-parametric Mann-Whitney U test was used for
PDGFRa and P-SMAD2/3 or TCF4 in DMD muscle.
DGFRa and vWF, PAX7, or CD45 in DMD muscle. Nuclei are stained
nd analyzed for the expression of the indicated genes. Values are
d t test was used for comparison.
D45 in adult ColI-GFP/mdx muscle after treatment with the TGFb
on shows fibrosis reduction and increased regeneration and vascu-
on-parametric Mann-Whitney U test was used for comparison. Scale
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fate and acquisition of mesenchymal traits centered on the
PDGFRa-expressing cell could be envisioned. How to
restrict deleterious PDGFRa-dependent functions while
preserving the beneficial ones is likely to be more
challenging.
Our findings support the notion that, in chronic degen-
erative conditions, the ability of specialized cells (such as
myogenic, endothelial, and inflammatory cells) to undergo
mesenchymal transitions is inversely correlated to the
degree of tissue regeneration, while facilitating fibrogene-
sis. This has implications for regenerative medicine, as
our findings unravel a physiological form of plasticity
that can be co-opted toward disease-associated tissue
degeneration and aging.EXPERIMENTAL PROCEDURES
Mice
Mdx mice were maintained in C57BL/10 or DBA/2 backgrounds.
Lineage-tracing mice have been described previously as follows:
Cdh5-CreER (Wang et al., 2010), Tie2-Cre transgenic (Kisanuki
et al., 2001), Pax7-Cre and Pax7-CreER (Nishijo et al., 2009),
R26R-EYFP (Srinivas et al., 2001), and Col1a1-3.6GFP (Coll-GFP)
(Krempen et al., 1999). Lineage-tracing mice were intercrossed
with C57BL/10 or DBA/2 dystrophic mdx mice (Fukada et al.,
2010). When needed, Cre activity was induced by intraperitoneal
injection (one injection per day for 4 days) with 5 mg/25 g body
weight tamoxifen (TAM) (Sigma; 10 mg/ml in corn oil). Bone
marrow transplantation experimentswere performed as previously
described (Perdiguero et al., 2011), using Coll-GFP mice as bone
marrow donor and mdx/C57BL/10 at 3 months of age as recipient
mice; mice were aged for 18 months for fibrosis development.Induction of Muscle Regeneration and Fibrosis
Regeneration of skeletal muscle was induced by intramuscular in-
jection of 50 ml 105 M CTX (Latoxan). Muscles were collected at
the indicated times on each set of experiments, which was usually
2 weeks after myotoxin injection. Contralateral control muscles
were left un-injured. To induce amore severe fibrotic injury, tibialis
anterior (TA) muscles of WT mice were subjected to laceration as
previously described (Ardite et al., 2012). To exacerbate fibrotic
muscle damage, 50 ng TGFb (recombinant TGFb1 and TGFb2,
R&D Systems) was injected into previously injured (or dystrophic)
TA and gastrocnemius muscle in a volume of 50 ml PBS, as previ-
ously described (Pessina et al., 2014). For the inhibition of TGFb,
LY2157299 (a specific inhibitor of the TGFb receptor type 1 kinase)
(Zhou et al., 2011) was administered to old mdx mice (in the
Coll-GFP background) for 30 days at a 25 mg/kg daily dose, and
different parameters were analyzed thereafter. For the inhibition
of PDGFRa signaling, imatinib (a tyrosine kinase inhibitor), which
has been shown to target PDGFRa-expressing mesenchymal pro-
genitor cells (Ito et al., 2013; Uezumi et al., 2014), was adminis-
tered to 7-day-CTX-injured mice for an additional 7-day period
(50 mg/kg daily), coinciding with the administration of TGFb,
and analyzed subsequently.1058 Stem Cell Reports j Vol. 4 j 1046–1060 j June 9, 2015 j ª2015 The AutCell Culture and Differentiation
Primary myoblasts were obtained from mouse skeletal muscle,
grown in Ham’s F10 medium (BioWest) supplemented with 20%
fetal bovine serum (FBS) and basic fibroblast growth factor (bFGF,
0.025 mg ml1), as described previously (Perdiguero et al., 2011).
Primary endothelial cells were grown in high-glucose DMEM
(BioWest) supplemented with 10% FBS and 10 ng/ml vascular
endothelial growth factor (VEGF), as described previously (Ieroni-
makis et al., 2008). Human myoblasts were purchased from Cook
Myosite and cultured following the provided instructions. When
indicated, cells were treated with TGFb1 (myoblasts) or TGFb2
(endothelial cells) (10 ng/ml). To induce differentiation into
distinct lineages, cells were grown in StemXVivo osteogenic and
adipogenic culture media (R&D Systems), after 4 days of TGFb
treatment. Alkaline phosphatase staining to detect osteoblasts
was performed with the alkaline phosphatase kit (Sigma-Aldrich)
on cultures grown in osteogenic medium for 14 days. Oil red O
(Sigma-Aldrich) staining to detect adipocytes was performed on
cultures grown in adipogenic medium for 14 days. Alternatively,
for fibrogenic differentiation, cells were cultured in TGFb-contain-
ing medium for an additional 7-day period.Statistical Analysis
Statistical analysis was performed with GraphPad Prism software
using the nonparametric Mann-Whitney U test or unpaired t test
for independent samples, with a confidence level of 95% being
considered statistically significant. The results are expressed as
mean± SEM. Thenumber of samples analyzed per group is detailed
in each figure.
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